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Abstract: Obesity is the most prevalent noncommunicable disease in the 21st century, associated 
with triglyceride deposition in hepatocytes leading to nonalcoholic fatty liver disease (NAFLD). 
NAFLD is now present in around a third of the world’s population. Epidemiological studies 
have concluded that ethnicity plays a role in complications and treatment response. However, 
definitive correlations of ethnicity with NAFLD are thoroughly under-reported. A comprehen-
sive review was conducted on ethnic variation in NAFLD patients and its potential role as a 
crucial effector in complications and treatment response. The highest NAFLD prevalence is 
observed in Hispanic populations, exhibiting a worse disease progression. In contrast, African-
Caribbeans exhibit the lowest risk, with less severe steatosis and inflammation, lower levels 
of triglycerides, and less metabolic derangement, but conversely higher prevalence of insulin 
resistance. The prevalence of NAFLD in Asian cohorts is under-reported, although reaching 
epidemic proportions in these populations. The most well-documented NAFLD patient popu-
lation is that of Caucasian ethnicity, especially from the US. The relative paucity of available 
literature suggests there is a vital need for more large-scale multi-ethnic clinical cohort studies 
to determine the incidence of NAFLD within ethnic groups. This would improve therapy and 
drug development, as well as help identify candidate gene mutations which may differ within 
the population based on ethnic background.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is an emerging public health concern in 
affluent economies and is defined by liver fat infiltration greater than 5%–10% of 
liver weight. It describes a spectrum from uncomplicated fatty liver (no liver injury), 
through nonalcoholic steatohepatitis (tissue inflammation) to liver cirrhosis.1 In the US, 
its prevalence in adults has risen from 18% in 1988–1991, to 29% in 1999–2000, and 
to 31% in 2011–2012.2 Mean age in this cohort was 48 years, and 45.8% of NAFLD 
patients according to the Third National Health and Nutrition Examination Survey 
were female. Currently, an estimated 1 billion people are now affected by NAFLD 
worldwide.3 NAFLD cannot be considered a disease only prevalent in affluent Western 
countries, as high rates of NAFLD are reported in the Middle East (32%) and South 
America (31%) followed by Asia (27%). Lower prevalence is observed in the US (24%) 
and Europe (23%), and rates are reported at 14% in Africa.4 Overall, NAFLD was most 
prevalent in 70–79 year-olds, where 33.99% of patients according to a meta-analysis 
were affected.4 This review focuses on exploring ethnic heterogeneity in NAFLD to 
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uncover factors that may be contributing to the global vari-
ance of disease burden.
The only treatment currently recommended for patients 
diagnosed with NAFLD is lifestyle change such as exercise or 
diet-induced weight loss. Recent studies have shown reduced 
prevalence of liver damage of at-risk patients receiving statin 
treatment.5 Metformin, ursodeoxycholic acid, and orlistat 
have also been shown to be beneficial.6–8 Antioxidants seem 
to have some limited efficacy in treating NAFLD, and an 
increasing number of trials have demonstrated improvements 
in enzyme abnormalities in patients taking vitamins A, B, D, 
and E.9 In practice, some clinicians recommend these patients 
to take vitamin E as a therapeutic option. Further emerging 
management options include, among others, angiotensin 
receptor blockers and α1 adrenoceptors antagonists.10
Without any reliable test, the presence of NAFLD is 
largely determined by histological and radiological confir-
mation of hepatic steatosis with the exclusion of excessive 
alcohol intake. Biopsies show principal features of NAFLD: 
peri-sinusoidal fibrosis, microvesicular steatosis, lobular 
inflammation, hepatocellular ballooning, and the absence 
of lipogranulomas.11
The metabolic syndrome seems to also be strongly cor-
related with NAFLD. This is comprised of glucose intoler-
ance, central obesity, hypertriglyceridemia, low levels of 
high-density lipoprotein (HDL), and hypertension. Most 
individuals with NAFLD will exhibit some of these character-
istics, with 65–71% of patients being obese, 57–68% having 
disturbed lipid profiles, 36–70% suffering from hypertension, 
and 12–37% with impaired fasting glucose tolerance. As a 
result of this association, NAFLD is widely considered a 
further feature of the metabolic syndrome.12,13 As many as 
70–75% of type two diabetes mellitus patients, and as high 
as 95% of obese patients have clinical signs of NAFLD.14
An important factor driving the development of NAFLD 
is lifestyle changes of populations across the globe. Eco-
nomic success, access to media, travel, and modernization 
in personal as well as professional lifestyles have led to an 
overall more sedentary lifestyle. Readily available calorie 
sources have contributed to excessive consumption in many 
countries, for example, India and China have been greatly 
affected by these trends.3 The perception of food and calo-
ries as well as cultural influence and resource availability 
accounts for greatly differentiated epidemiology of NAFLD 
across the countries.
Although many environmental risk factors are implicated 
in ethnic variations of NAFLD, more research focusing on 
the genetic background of NAFLD is required. Multivariable 
models adjusted for sex, age, and ethnicity have shown 52% 
heritability rates of NAFLD, but evidence for specific genetic 
mutations is sparse.3 The patatin-like phospholipase domain-
containing protein 3 (PNPLA3) gene, otherwise known as 
adiponutrin, has been identified to be responsible for increased 
hepatic triglyceride levels, fibrosis, and inflammation. This is 
currently regarded as the only confirmed gene heterogeneity 
underpinning ethnic differences in NAFLD.15 Homozygote 
patients have a two-fold increase in hepatic fat content com-
pared to those not carrying the allele. Hispanic populations 
seem to have the highest frequency of this polymorphism, 
with almost 49% reported as carriers, compared to 23% in 
Caucasian and 17% in black patients in studies.16,17 Mutations 
in the Hemochromatosis (HFE) gene have also been commonly 
associated with developing NAFLD. The HFE gene is respon-
sible for iron uptake and transferrin plasma concentration, and 
the association with NAFLD may be due to iron deposition in 
the liver, though the mechanisms of this remain unclear.18,19
Several other factors have been identified in the devel-
opment and subsequent outcomes of NAFLD. Epigenetic 
alterations, maternal nutrition during pregnancy, gut micro-
biota, and reactive oxygen species have been suggested to 
be of importance.20–25 However, results for racial and ethnic 
differences in oxidative stress levels are inconsistent. Ito et 
al26 found higher lipid peroxidation among Japanese in the 
US compared to Caucasians, and Block et al27 found African 
American individuals to have a significantly lower level of 
lipid peroxidation. Additionally, changes to innate immunity 
are implicated in patients with NAFLD. Studies have shown 
an increased number of Kupffer cells (KC); however, these 
KC showed defective function.22 Some studies also report a 
decreased number of natural killer T cells.28
It is crucial to examine disease-progression and fac-
tors that modify this in NAFLD. While fibrosis seems to 
be associated with the natural progression of NAFLD over 
time, patients may remain stable for several years, provid-
ing a potential window for intervention.29,30 It is important 
to note that increased BMI and insulin resistance have been 
associated with a more rapid progression to fibrosis, which 
may eventually result in the patient requiring liver trans-
plantation.31,32 The UK National Health Service Blood and 
Transplant agency has reported an increase in the proportion 
of patients undergoing surgery due to nonalcoholic steato-
hepatitis, where the liver has become inflamed following 
fat accumulation (12% in 2013 compared to 4% in 1995).33 
Furthermore, the death of those patients with cirrhotic stage 
nonalcoholic steatohepatitis, where the liver has become 
inflamed following fat accumulation is most likely related to 
end-stage liver disease within 4–10 years of follow-up.34 A US 
community-based study of 103 NAFLD patients reported that 
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37% of patients progressed to liver fibrosis within a mean of 
3.2±3.0 years.35 A meta-analysis found an increased mortality 
within NAFLD patients (OR=1.57) attributed to liver-related 
or cardiovascular causes, and a two-fold risk of developing 
diabetes.36 A Swedish study by Söderberg et al37 followed 
256 patients with positive biopsies for approximately 28 
years, and reported an overall increased mortality ratio of 
1.69. They concluded that patients with mild steatosis had a 
55% higher risk of mortality, and patients with moderate-to-
advanced fibrosis had an 86% higher risk compared to the 
general population. Finally, in a meta-analysis of five obser-
vational studies of 1,495 biopsy-proven NAFLD patients, an 
exponentially higher risk of mortality was observed, and the 
mortality risk progressively increases with fibrosis stage.38
There is evidence suggesting significant variation in the 
risk of developing NAFLD as well as differences in disease 
progression due to ethnic background. This has been argued 
to act as a potential independent risk factor for disease sever-
ity, along with advanced age and male sex.39 However, there is 
a need for an up-to-date analysis, as these associations could 
potentially serve as an important and novel clinical viewpoint, 
and may aid the refinement of management options.
This review summarizes available evidence to support, 
and suggests potential causes for the significant variation 
in prevalence and severity of NAFLD observed in differ-
ent ethnic groups. We interrogated literature on NAFLD in 
African-Caribbean, Caucasian, Hispanic, East Asian, and 
South Asian ethnic groups (see Table 1), and uncovered that 
different ethnic groups in NAFLD patients may contribute 
to an improved understanding of pathogenesis and manage-
ment of the disease, and thus improve long-term outcomes.
Afro-Caribbean ethnic group
For this review, Afro-Caribbean ethnicity is defined as an 
individual of African descent, living in or coming from 
Africa or the Caribbean region. Contrary to observed preva-
lence of metabolic disease and obesity in Afro-Caribbean 
populations, several studies have shown a relative sparsity of 
NAFLD cases among these groups compared to Caucasian 
and Hispanic populations.40,41 However, as Caldwell et al42 
argues, it is hard to tell if the discrepancy might simply 
arise from “under-recognition, under-referral or a truly 
lower prevalence” in these ethnic groups, as Afro-Caribbean 
patients are empirically less likely to be referred to health 
services.43
Evidence suggests that, in Afro-Caribbean populations 
of NAFLD patients, liver biopsies show less steatosis, and 
decreased inflammation when compared with biopsies from 
Caucasian patients.44 Additionally, Afro-Caribbean patients 
with NAFLD were shown to be affected by hypertension more 
commonly compared to Caucasian or Hispanic patients.45 
For metabolic profiles, Afro-Caribbean patients were found 
to have lower levels of triglycerides and significantly lower 
serum HDL compared to other ethnic groups.46 This corre-
lates to less metabolic derangement in these cohorts. Afro-
Caribbean patients also have less visceral fat, which appears 
to contribute to a lower risk of developing advanced liver 
pathology after the diagnosis of NAFLD.47,48 However, the 
literature showed that, despite lower grade hepatosteatosis, 
Afro-Caribbean individuals had a similar prevalence of 
insulin resistance compared to Hispanics, who were found 
to have the highest level of hepatic fat content.32
Some specific transcriptomic profile differences have been 
isolated between Afro-Caribbean and Caucasian populations, 
which may contribute to the different metabolic makeup. In 
a study of 94 patients undergoing bariatric surgery, there 
was over-expression of CYP/CYP450 (CYP3A), insulin-like 
growth factor (IGF2), acyl-CoA synthetase long chain family 
member 4 (ACSL4), fumarylacetoacetate hydrolase (FAH), 
fucosyltransferase 4 (FUT4), erythrocyte membrane protein 
band 4.1 (EPB41L1), glutathione transferase 2 (GSTM2), 4 
(GSTM4), and 5 (GSTM5).40 These genes are responsible 
for the coding of monooxydases, peroxidases, catalysis 
of tyrosine, glycolysis, and detoxification of electroliphic 
compounds. Differences in the coding of these genes thus 
may contribute to pathologies associated with the metabolic 
syndrome, such as NAFLD. Indeed, GSTM2, GSTM4, and 
GSTM5 have previously been implicated in the pathogenesis 
of the condition.40 Heritable missense variants in PNPLA3 
and glucokinase regulator gene (GCKR) have been identified 
by another study, which was shown to be associated with a 
predisposition to hepatic steatosis across ancestries in both 
African and Hispanic Americans.15
east Asian ethnic group
In this review, East Asian ethnic groups were defined as: those 
with Chinese, Japanese, Taiwanese, Indonesian, and Korean 
ethnic backgrounds. The management of obesity-associated 
conditions is swiftly becoming a public health issue in this 
cohort. There are several potential factors contributing to this 
phenomenon; increased diagnosing or the wider availability 
of “Western” diets with more energy-dense food consumption 
are among the most often-cited culprits.49 NAFLD among 
East Asians has been widely studied in large scales. However, 
only a few studies compare this cohort with patients from a 
Caucasian, Hispanic, or African origin.44,50,51
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Chinese individuals have been shown to have higher 
body fat percentages than Caucasian controls for any given 
BMI, and have also been reported to have a higher visceral 
adiposity and subcutaneous body fat overall. Conversely, 
patients affected by NAFLD have been shown to have lower 
BMI than patients from other ethnic backgrounds.52 This 
is consistent with the now generally recognized fact that 
obesity-related metabolic disorders begin at much lower 
levels of BMI in those of Asian descent. For this reason, some 
health care professionals now adapt a lower BMI threshold 
for clinical assessment and referral in these patients.53,54 
A meta-analysis of 48 studies, conducted between 1997 
and 2013, and including 356,367 subjects in China, found 
a pooled prevalence of NAFLD of approximately 20% in 
healthy cohorts (18–22%).55
In Japan, a study found that the prevalence of NAFLD 
was 25% in 2005, compared to figures of 12.6% in 1989, 
indicating a rapid rise in NAFLD prevalence.56 Some annual 
health checks show that as many as 9–30% of Japanese adults 
have evidence of NAFLD on ultrasonography.57 However, 
a research article using a model to predict changes in the 
prevalence of NAFLD found that the number of cases in 
Japan will show a 2.6% decrease by 2030.58 Nevertheless, 
the rising prevalence of NAFLD in Japan is not negligible.
In Korean adults, the study of NAFLD prevalence com-
pared to other ethnic groups is even less. One study stated 
a 18.7% prevalence (23% in men and 13.7% in women), 
investigating 6,648 subjects by ultrasound scanning.59 Within 
East-Asia ethnic groups, Taiwanese individuals were found 
to have the lowest prevalence: a study enrolling 3,245 Tai-
wanese adults from a rural village found that the prevalence 
of NAFLD was 11.5%, based on blood tests and ultraso-
nography. Other studies reported ranges as high as 11–41%, 
which is similar to that of other Asian countries.60 Indonesian 
individuals were found to have the highest prevalence (30%) 
of NAFLD among East-Asian ethnic groups.61
East Asian NAFLD patients seem to develop more signifi-
cant pathological changes on liver biopsies. On histological 
data, East Asian individuals were almost three times as likely 
(OR=2.67) to develop high grades of ballooning of hepato-
cytes, with higher grades of inflammation.44 One possible 
explanation for this observation may be Apolipoprotein C3 
(APOC3) gene polymorphisms, which have been identified to 
correlate with hepatic fat accumulation in Asian populations. 
Studies conducted in other ethnic groups did not replicate this 
genotype-phenotype association. It is, therefore, plausible 
that APOC3 genotypes are solely linked with NAFLD within 
Asian patient populations, contributing to the explanation 
of ethnic variations of NAFLD.62 Ethnic differences have 
not been thoroughly investigated, but a study of 2,410 male 
Korean individuals has shown that serum ferritin levels pre-
dicted incidental findings of hepatic steatosis, and, therefore, 
may also be significant in these populations.63
NAFLD in these populations developed within a much 
shorter period and within a younger patient population and 
lower BMI.49 Different rates of obesity have been recorded 
within subgroups of East-Asia, suggesting that different 
stages of urbanization are a strong confounding factor, as well 
as genetic differences. The effect of the Asian diet needs to 
be explored in greater depth, as the study of the influence of 
nutritional factors may be of importance in these cohorts.64 
There has been a rapid economic growth, especially in Japan, 
and this could bring about a shift in lifestyle and diet prefer-
ences. This may partially explain the “obesity epidemics” 
observed in these countries, as these populations are tradi-
tionally adapted to a different diet compared to the West. 
Historically, Asian diets largely consist of low levels of fat and 
meat, and are mainly vegetable-based with rice as the staple 
carbohydrate. Thus, over-nutrition and the consumption of 
energy-dense food may contribute greatly to the accelerated 
and more significant development of obesity-associated liver 
changes in these cohorts.65
Identifying susceptibility factors in East-Asian individu-
als is important, and a personalized approach needs to be 
taken when managing these patients.
South Asian ethnic group
South Asian populations (Indian, Bangladeshi, Pakistani, 
Nepalese, Sri Lankan, and Malaysian) have high rates of 
diabetes, insulin resistance, and other obesity-associated 
pathology when compared with Western populations. Indeed, 
India has been ranked as the country with the highest number 
of individuals with diabetes worldwide.66 This ethnic group is 
investigated separately from other Asian countries because of 
the potential differences in diet, economic status, and growth, 
as well as other confounding factors.
There are at least 25 million NAFLD patients in India 
alone, which is a country with a population of more than 
1.324 billion people.67 However, there are only limited 
data on South Asian NAFLD patients compared with other 
ethnic groups.68 This could be due to the fact that, in some 
developing parts of these countries, a large component of 
hepatobiliary disease burden is viral hepatitis, reducing the 
priority accorded to NAFLD.69
It has been shown that South Asians have a more adverse 
body fat distribution and are more likely to have dyslipidemia 
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than Western patients.70,71 A study investigating samples from 
100 Asian Indian NAFLD patients suggested a significant 
difference in the pathological profile, when compared with 
studies on Western patients.68 An overall lower average body 
weight was observed, and, contrary to Caucasian patients, 
diabetes mellitus was not strongly associated with the 
development of the disease. This is often referred to as the 
“Asia paradox”, describing the observation that South Asian 
patients with NAFLD have an overall lower BMI. The average 
BMI of these patients is only 26, and BMI has been shown 
to not represent the true risk of developing the condition.72 
PNPLA3 single nucleotide polymorphisms were associated 
with increased hepatic fat content in South Asian ethnic 
groups, particularly in Asian Indians according to studies.73 
Other contributing factors may include physical inactivity, 
reduced disease awareness, and health-seeking, delayed 
diagnosis, and religious and sociocultural factors between 
these and Western patient populations.74
Studies have shown that Indian NAFLD patients were 
younger and had lower prevalence of diabetes mellitus com-
pared to Caucasian cohorts, with similar necro-inflammatory 
activity and levels of fibrosis.75 Several studies have con-
cluded, however, that insulin resistance and the metabolic 
syndrome were similarly indicated in these cohorts as other 
ethnic groups.76 Iron abnormalities were not significantly 
observed in this population group.77 Several other epidemio-
logical studies cited a prevalence of 16–30% in South-Asian 
populations.78
Pakistani patients had high odd ratios (OR=1.31) of 
developing NAFLD, but, surprisingly, Indian study subjects 
were found to be less likely to be diagnosed with the condition 
than those of other ethnic groups.78 In Indian men, insulin 
resistance seems to be 2–3-fold higher than other ethnic 
groups, leading to a 2-fold increase in hepatic triglyceride 
content compared to Caucasians.79 This may imply important 
ethnic differences in insulin resistance and its association 
with NAFLD. Bangladeshi patients were more frequently 
diagnosed with NAFLD, with one study reporting prevalence 
as high as 34.34%.80
In conclusion, South-Asian individuals seem to be at a 
much higher risk of developing NAFLD when compared to 
Caucasians individuals.81
Hispanic ethnic group
The most extensive evidence available on the ethnic varia-
tions of NAFLD is that of its prevalence in Hispanics, defined 
as “Spanish-speaking” individuals of Central and South 
American origin. Several studies have shown that NAFLD is 
disproportionately frequent in Hispanic minorities compared 
to Caucasian or Afro-Caribbean patients.82–86 This ethnic 
disparity seems to be independent of age, and studies have 
shown that children and adolescents of Hispanic heritage have 
similarly high incidence of NAFLD compared to their non-
Hispanic peers.87 In fact, mortality rates in Hispanic popula-
tions from the US due to cirrhosis have been reported to be 
almost 2-fold greater than non-Hispanic white populations, 
however deaths from alcoholic liver disease were included 
in these studies.88,89 In another study, Hispanic patients were 
more than twice as likely to show higher grades of ballooning 
and Mallory bodies, respectively, than Caucasians and other 
ethnic groups combined. Thus, in these cohorts, the evidence 
shows that NAFLD is not only more prevalent, but may also 
have a worse diagnosis.44
There seems to be variation in prevalence among His-
panic patients of different heritage, although little is known 
of the distribution of NAFLD among Hispanic subgroups. 
Individuals with a Cuban, Puerto Rican, and Dominican 
heritage seem to have lower prevalence of suspected NAFLD 
than Central-, South American, and Mexican populations.90 
Riquelme et al91 found that 23% of Chilean Hispanics had 
evidence of NAFLD on ultrasound in the absence of Hepa-
titis infection or alcohol consumption. Serum and radiologi-
cal evidence from the multi-ethnic study of atherosclerosis 
(MESA) cohort study concluded that Mexican Hispanics 
had a 2-fold prevalence (33%) of NAFLD compared to 
individuals of Dominican (16%) and Puerto Rican origin 
(18%).92 The reasons for these variations within the ethnic 
group are unclear, but may point to genetic background, 
different levels of insulin resistance, and lifestyle factors 
as main contributing factors.
One explanation for higher rates of NAFLD in Hispan-
ics may be that these individuals seem to have a higher BMI 
overall compared to other ethnic groups.93 When compared 
to women with similar BMI and socioeconomic status, His-
panic women have also been found to have a higher level of 
adiposity.94 Likewise, socioeconomic and cultural risk factors 
have been indicated in these cohorts. Evidence shows that 
residence in high-poverty areas is correlated with higher 
prevalence of lower-cost sugar and fat-rich foods and drinks, 
factors especially prevalent in Latino communities. Accord-
ing to 2015 census data, one in four Latino adults lived at or 
below the poverty line (22.6%), a figure more than twice as 
high as non-Latino ethnic groups (10.4%).95
Some genetic influences have been uncovered, and a 
genome-wide association study (GWAS) study by including 
samples from 248 Hispanic children has found associations 
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of several genetic loci with the diagnosis of NAFLD on chro-
mosomes 8, 14, and 20.96 A further GWAS study showed a 
positive correlation of a PNPLA3 gene variant with hepatic 
fat content, a polymorphism known to be more common 
in Latinos compared with other ethnic groups.97 A GWAS 
study conducted in the US investigating genetic markers in 
Hispanic women attained strong correlations with farnesyl-
diphosphate farnesyltransferase one within these cohorts, a 
gene that regulates cholesterol homeostasis, which could be 
a contributing factor to the ethnic disparity.98 However, more 
focused research is required to interrogate genetic as well as 
metabolic differences within these cohorts, with a focus on 
Hispanics of varying heritage.
Caucasian ethnic group
Although incidence of NAFLD in Caucasians in the US is 
well-documented and well-researched, few studies investigate 
discrepancies within Caucasian cohorts of different countries. 
Notably, within Europe, most forms of hepatitis have been 
demarcating a gradient of increasing prevalence; however, 
this does not seem to be the case for NAFLD.99
The DIONYSOS study found NAFLD prevalence to be 
20–25% within Italian cohorts, and a Greek study found 
NAFLD to be 31% in autopsy reports.100,101 NAFLD is 
estimated to be present in 20% of Romanians.102 In obese 
patients, NAFLD was diagnosed in as high as 20–30% of 
Caucasian cohorts.103
Poor dietary habits, especially a typical Western diet 
(incorporating high intakes of red or processed meat, full-fat 
products, fried food, refined cereals, sugar, and soft drinks) 
has been correlated with and believed to be a cornerstone in 
the development of NAFLD in Caucasian cohorts, as well 
as other ethnic groups. However, the role of specific dietary 
patterns has not been formally investigated. One study com-
pared 995 adolescents following healthy and Western diets, 
respectively. Participants were interviewed at 14 years, and 
then followed up with a liver ultrasound at 17 years. This 
study found that a Western dietary pattern at 14 years was 
associated with the development of NAFLD at 17 years 
(OR=1.59), and found a healthy diet protective.104 Recently, 
significant association was found by a meta-analysis between 
sugar-sweetened soda consumption and developing NAFLD, 
a staple in economically advanced Western countries.105 A 
meta-analysis reviewing 21 population-based surveys has 
found that the prevalence of NAFLD was positively cor-
related with gross national income, thus Europe exhibited a 
much higher prevalence in all studies (28% compared to 13% 
in Middle East and 19% in East-Asia). In this study, urban 
living was also contributing to these prevalence rates, signify-
ing a strong link between economic success and NAFLD.106
Some studies have interrogated genetic discordance in 
Caucasian-only cohorts. A large GWAS study comparing 
results from three distinct European ancestry studies pre-
viously reported associations with PNPLA3 and GCKR, 
but also uncovered two novel gene loci associations near 
PPP1R3B and NCAN.107 Feldman et al108 compared Cauca-
sian lean individuals with NAFLD with those without, and 
found significant differences in the subjects with the disease. 
Whilst their fasting insulin concentrations were similar to 
the healthy cohort, they had marked glucose tolerance and 
higher rates of PNPLA3 allele mutations. Certain lysophos-
phatidylcholines were also indicated to be of importance in 
the study, as well as lysine, tyrosine, and valine. Uncovering 
protective factors of Caucasian ethnic descent compared 
to Asian and Hispanic patients may greatly contribute to 
decreasing NAFLD disease burden in the Western countries.
Conclusion
NAFLD is a spectrum of liver disease, which is set to 
become the most prevalent cause of liver transplant globally 
by 2020.109 There is a greater risk of the disease in Asian 
and Hispanic ethnic groups, and this can be directly linked 
to metabolic factors, genetic predisposition, as well as the 
environment. Table 2 summarizes the differences our study 
has concluded within these cohorts. However, specific 
effectors and their individual contributions remain unclear. 
It is important to note that the majority of studies defined 
and diagnosed NAFLD using surrogate measures, such as 
liver enzymes and imaging. Few of the included studies 
have used biopsies as an indicator, which remains the gold 
standard for diagnosis. The specificity of liver enzymes is 
limited, as is the use of ultrasound, and this may result in 
uncertain prevalence estimation of NAFLD.110 Most of the 
studies reviewed utilized primary data collection done by 
the Third National Health and Nutrition Examination Survey 
(1988–1994), or MESA (2002–2005), which may produce 
outdated results.2,50,51,84,86,111 Prevalence of NAFLD, thus, 
in current, prospective population-based studies, may be 
higher.
Specific ethnic groups that have different heritages 
should be compared in large cohort studies, using biopsies 
for measure of disease. This would aid the identification of 
contributors to susceptibility of developing NAFLD, vari-
ability in gene mutations, as well as provide a larger patient 
sample for shared biomarker discovery. Furthermore, with 
increasing rates of NAFLD in children and adolescents, 
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studies should further focus on the interplay between devel-
opmental, genetic, and environmental factors.
This review summarized the literature available inves-
tigating ethnic variations in the development of this highly 
prevalent but widely unrecognized noncommunicable dis-
ease. Although there are several population-based cohort 
studies investigating ethnic variations in the pathogenesis 
of NAFLD, large-scale multi-ethnic clinical studies are 
vital for targeted therapy and drug development.112 Iden-
tifying and outlining high-risk populations would aid 
clinicians to successfully adapt screening and prevention 
programmes. A more targeted approach also needs to be 
taken to interrogate genetic crosstalk within the genome, 
to uncover more generalizable patterns within our genetic 
makeup, and their effect on susceptibility to obesity-
related illnesses. This would help develop strategies for 
the implementation of public health policies in different 
geographical areas.
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